Skip to content
Sign in

EXEL · NASDAQ

Exelixis (EXEL) Stock Price & Fundamentals

$269.52−0.43%−$1.17End-of-day price as of Oct 9, 2026

Exelixis (EXEL) closed at $269.52 on Oct 9, 2026, down 0.43% from the previous close of $270.69.

Share price, past year

1Y +4.11%

52-week range $251.81 – $293.35. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$269.52
Sep 30, 2026$271.50
Aug 31, 2026$272.21
Jul 31, 2026$272.35
Jun 30, 2026$280.60
May 29, 2026$262.52
Apr 30, 2026$284.51
Mar 31, 2026$284.23
Feb 27, 2026$286.41
Jan 30, 2026$277.83
Dec 31, 2025$268.10
Nov 28, 2025$254.27
Oct 31, 2025$259.89

Key statistics

Market cap
$67.08B
P/E (TTM)
84.5
EPS (TTM)
$3.19
Revenue (TTM)
$2.44B
Net income (TTM)
$860.62M
Shares outstanding
248.9M
Dividend yield
—
52-week range
$251.81 – $293.35

Exelixis's market cap is $67.08B, based on a share price of $269.52 and 248.9M shares outstanding as of Jul 3, 2026.

Financials

Exelixis reported revenue of $2.32B for fiscal 2025, up 6.98% from fiscal 2024.

Exelixis earned net income of $782.57M in fiscal 2025, a net margin of 33.7%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY20FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Exelixis annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Jan 2, 2026$2.32B+7.0%$782.57M33.7%$2.78$875.84M
FY2024ended Jan 3, 2025$2.17B+18.5%$521.27M24.0%$1.76$671.54M
FY2023ended Dec 29, 2023$1.83B+13.6%$207.77M11.4%$0.65$292.86M
FY2022ended Dec 30, 2022$1.61B+12.3%$182.28M11.3%$0.56$334.91M
FY2021ended Dec 31, 2021$1.43B+45.3%$231.06M16.1%$0.72$346.58M
FY2020ended Jan 1, 2021$987.54M+2.0%$111.78M11.3%$0.35$178.64M
FY2020ended Jan 3, 2020$967.78M+13.4%$111.78M11.6%$0.35$178.64M
FY2018ended Dec 28, 2018$853.83M+88.7%$690.07M80.8%$2.21$382.42M
FY2017ended Dec 29, 2017$452.48M+136.3%$154.23M34.1%$0.49$144.47M
FY2016ended Dec 31, 2016$191.45M—−$70.22M−36.7%−$0.28$204.59M
Exelixis quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jul 3, 2026$628.69M$212.05M$0.82
Q1 FY2026ended Apr 3, 2026$610.81M$210.47M$0.79
Q4 FY2025ended Jan 2, 2026$598.66M$244.53M$0.89
Q3 FY2025ended Oct 3, 2025$597.76M$193.58M$0.69
Q2 FY2025ended Jul 4, 2025$568.26M$184.85M$0.65
Q1 FY2025ended Apr 4, 2025$555.45M$159.62M$0.55
Q4 FY2024ended Jan 3, 2025$566.76M$139.86M$0.47
Q3 FY2024ended Sep 27, 2024$539.54M$117.97M$0.40

Company profile

Name
Exelixis, Inc.
Ticker
EXEL
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
1851 Harbor Bay Parkway, Alameda, CA 94502
Incorporated in
DE
Fiscal year ends
January
SEC CIK
0000939767

Recent SEC filings

Frequently asked questions

What is Exelixis's stock price?

Exelixis (EXEL) closed at $269.52 on Oct 9, 2026, down 0.43% from the previous close of $270.69.

What is Exelixis's market cap?

Exelixis's market cap is $67.08B, based on a share price of $269.52 and 248.9M shares outstanding as of Jul 3, 2026.

How much revenue does Exelixis make?

Exelixis reported revenue of $2.32B for fiscal 2025, up 6.98% from fiscal 2024.

What is EXEL's P/E ratio?

Exelixis's price-to-earnings ratio is 84.5, based on trailing twelve-month diluted EPS of $3.19.

Does Exelixis pay a dividend?

Exelixis's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Exelixis, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures